nyuuzyou/wikis huggingface dataset:
Cobimetinib (Cotellic)

==General information==
Class/mechanism: Tyrosine kinase inhibitor, MEK1 (mitogen-activated extracellular signal regulated kinase 1) and MEK2 inhibitor. Cobimetinib inhibits the mitogen-activated protein kinase (MAPK)/extracellular signal-related kinase (ERK) pathway by inhibiting MEK1 and MEK2. Cancers with BRAF V600E and K mutations have constitutive activation of the BRAF pathway, which includes MEK1 and MEK2. Inhibiting MEK1 and MEK2 results in inhibition of ERK and cellular proliferation.Cobimetinib (Cotellic) package insert Cobimetinib (Cotellic) package insert (locally hosted backup)
Route: PO 
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Diseases for which it is used==
*BRAF-mutated melanoma
*Craniopharyngioma
*Erdheim-Chester disease
*Langerhans cell histiocytosis
*Rosai-Dorfman-Destombes disease
==Patient drug information==
*Cobimetinib (Cotellic) package insert
==History of changes in FDA indication==
*2015-11-10: Approved for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. (Based on coBRIM)
*2022-11-01: Approved for the treatment of adult patients with the family of blood diseases known as histiocytic neoplasms. These diseases include Erdheim-Chester disease, Rosai-Dorfman disease, and Langerhans cell histiocytosis. (Based on MSK 15-216)
==History of changes in EMA indication==
*2015-11-20: Initial authorization in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
==History of changes in Health Canada indication==
*2016-02-22: Initial notice of compliance 
==Also Known As==
*Code names: GDC-0973, XL-518
*Brand name: Cotellic
==References==
Category:Drugs
Category:Mutation-specific medications
Category:Oral medications
Category:MAP2K1 inhibitors
Category:MAP2K2 inhibitors
Category:Craniopharyngioma medications
Category:Erdheim-Chester disease medications
Category:Langerhans cell histiocytosis medications
Category:Melanoma medications 
Category:Rosai-Dorfman-Destombes disease medications
Category:EMA approved in 2015
Category:FDA approved in 2015
Category:Health Canada approved in 2016
Coltuximab ravtansine (SAR-3419)

==Mechanism of action==
From the NCI Drug Dictionary: An immunoconjugate consisting of an anti-CD19 monoclonal antibody conjugated to the maytansinoid DM4, a derivative of the cytotoxic agent maytansine (DM1), with potential antineoplastic activity. Anti-CD19-DM4 conjugate SAR3419 targets the cell surface antigen CD19, found on a number of B-cell-derived cancers. Upon antibody/antigen binding and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of CD19-expressing tumor cells.
==Preliminary studies==
===Diffuse large B-cell lymphoma===
# Abstract: B. Coiffier, V. Ribrag, J. Dupuis, H. Tilly, C. Haioun, F. Morschhauser, T. Lamy, C. Copie-Bergman, O. Brehar, R. Houot, J. M. Lambert, R. Morarui-Zamfir. Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients (pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). J Clin Oncol 29: 2011 (suppl; abstr 8017) link to original abstract
# Coiffier B, Thieblemont C, de Guibert S, Dupuis J, Ribrag V, Bouabdallah R, Morschhauser F, Navarro R, Le Gouill S, Haioun C, Houot R, Casasnovas O, Holte H, Lamy T, Broussais F, Payrard S, Hatteville L, Tilly H. A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. Br J Haematol. 2016 Jun;173(5):722-30. Epub 2016 Mar 24. link to original article PubMed
==Also known as==
*Code name: SAR-3419
*Generic name: CoR
Category:Drugs
Category:Intravenous medications
Category:Anti-CD19 antibody-drug conjugates
Category:Microtubule inhibitors
Category:Diffuse large B-cell lymphoma medications (investigational)
Category:Investigational drugs
Compression stockings and sleeves

=Indications for Gradient of Counterpressure=
==Gradient I (8-12 mm Hg)==
*Heaviness and fatigue in legs
==Gradient II (15-20 mm Hg)==
*Tired, aching legs
*Minor ankle, leg, and foot swelling
*Minor varicose veins
==Gradient III (20-30 mm Hg)==
*Prophylaxis and treatment of mild vascular insufficiencies
*Mild varicosities without significant edema
==Gradient IV (30-40 mm Hg)==
*Varicose veins
*Chronic venous insufficiency
*Peripheral edema
*Prophylaxis post surgical stripping
*Post-phlebitis syndrome
*Pregnancy-related varices
*Prophylaxis and treatment of edema and phlebitis due to post-fracture conditions and injury
*Postural hypotension
*Stasis dermatitis due to chronic venous insufficiency (CVI)
*Venous stasis ulcers
*Post-cast removal
*Post-ligation or stripping
*Inguinal lymphadenectomy
*Muscular inactivity
*Cellulitis
==Gradient V (40-50 mm Hg)==
*Severe, marked degrees of Gradient IV conditions
*Reversible lymphedema
*Complications of chronic venous insufficiency such as:
**Marked dependent edema
**Venous ulcers
**Severe chronic venous insufficiency
*Post-phlebitis syndrome
==Gradient VI (50-60 mm Hg)==
*Severe marked degrees of Gradient V conditions
*Severe post-thrombotic cases
*Irreversible lymphedema
=Compression therapy support styles=
*Knee length
*Thigh length
*Waist height—either 1 or 2-leg
*Maternity
*Lymphedema arm sleeve
*Lymphedema gauntlet (glove without fingers)
*Lymphedema glove
=Contraindications to compression therapy=
*Cutaneous infections
*Hypodermitis in the acute phase
*Wet dermatoses
*Massive edema from congestive heart failure
*Severe arterial insufficiency
Category:Supportive oncology
Concizumab (Alhemo)

==Mechanism of action==
Anti-TFPI antibody
==Supporting data==
*explorer7: Matsushita T, Shapiro A, Abraham A, Angchaisuksiri P, Castaman G, Cepo K, d'Oiron R, Frei-Jones M, Goh AS, Haaning J, Hald Jacobsen S, Mahlangu J, Mathias M, Nogami K, Skovgaard Rasmussen J, Stasyshyn O, Tran H, Vilchevska K, Villarreal Martinez L, Windyga J, You CW, Zozulya N, Zulfikar B, Jiménez-Yuste V; explorer7 Investigators. Phase 3 Trial of Concizumab in Hemophilia with Inhibitors. N Engl J Med. 2023 Aug 31;389(9):783-794. link to original article EuroPMC NCT04083781
==Also known as==
*Brand name: Alhemo
Category:Drugs
Category:Subcutaneous medications
Category:Anti-TFPI antibodies
Category:Inherited coagulopathy medications
Category:Health Canada approved in 2023
Category:Stub
Conflict of interest

==Introduction==
With the September 2018 expose in the New York Times on José Baselga, a leader in the field of breast oncology and medical oncology as a whole, public awareness of financial conflicts of interest in hematology/oncology is on the rise. Financial and other conflicts of interest are not new to biomedicine but can certainly diminish trust in the profession. We plan to develop this page as an archive of lay media and peer-reviewed literature covering the topic; it will be expanded over time.
==Widespread problems with disclosure of COI==
*12/8/2018: NYT: What These Medical Journals Don’t Reveal: Top Doctors’ Ties to Industry
==MSKCC and Paige.AI==
*9/20/2018: ProPublica: Sloan Kettering’s Cozy Deal With Start-Up Ignites a New Uproar
==José Baselga controversy==
*9/8/2018, NYT: Top Cancer Researcher Fails to Disclose Corporate Financial Ties in Major Research Journals
*9/13/2018, NYT: Top Sloan Kettering Cancer Doctor Resigns After Failing to Disclose Industry Ties
*9/14/2018, NYT: Transparency Hasn’t Stopped Drug Companies From Corrupting Medical Research
*9/15/2018, NYT: Medicine’s Financial Contamination
==What we are doing==
HemOnc.org was founded with the goal of creating a freely available, comprehensive, centralized repository of chemotherapy drug and treatment regimens. From the beginning, our philosophy has been to remain ad-free, revenue-neutral, and an international community resource without paywalls or registration requirements. In the interests of transparency, we will be adding financial conflict of interest disclosures to our Editorial Board page. If you have other thoughts about how we can maximize transparency, please contact us at contact@hemonc.org.
Category:General reference pages
Congenital thrombotic thrombocytopenic purpura

Back to Top
*We have moved How I Treat articles to a dedicated page.
Last updated on 2024-07-23:1 regimens on this page
1 variants on this page
=All lines of therapy=
==rADAMTS13 monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Scully et al. 2024 (cTTP)	2010-10 to 2014-01 	Phase 3 (E-switch-ooc)	Standard treatment	No acute TTP events
====Supportive therapy====
*ADAMTS13, recombinant (Adzynma)
===References===
# cTTP: Scully M, Antun A, Cataland SR, Coppo P, Dossier C, Biebuyck N, Hassenpflug WA, Kentouche K, Knöbl P, Kremer Hovinga JA, López-Fernández MF, Matsumoto M, Ortel TL, Windyga J, Bhattacharya I, Cronin M, Li H, Mellgård B, Patel M, Patwari P, Xiao S, Zhang P, Wang LT; cTTP Phase 3 Study Investigators. Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2024 May 2;390(17):1584-1596. link to original article EuroPMC NCT03393975
Category:Congenital thrombotic thrombocytopenic purpura regimens
Category:Disease-specific pages
Category:Cytopenias
Category:Thrombotic disorders
Consult topics in hematology and oncology

These are some topics which arise for hematology and oncology consultants:
==Blood counts==
*Neutropenia/leukopenia
*Leukocytosis
*Eosinophilia
*Anemia
*Peripheral smear findings
*Polycythemia
*Thrombocytopenia
*Thrombocytosis
*Transfusion medicine
==Hemostasis==
*Bleeding disorders and risk
*Hypercoagulable state (thrombophilia)
*Venous thromboembolism
==Oncologic emergencies==
*Brain metastases
*Cord compression
*Tumor lysis syndrome
Category:General reference pages
Contexts

The purpose of this page is to define treatment contexts used in the HemOnc ontology; it is not for other purposes at this time.
=FDA indication language=
==Early stage==
==Locally advanced==
==Advanced==
==Advanced or metastatic==
==Metastatic==
==Relapsed or refractory==
==Untreated==
AKA: Newly diagnosed
=Treatment contexts=
==Remission induction==
==Maintenance==
==First-line therapy==
==Second-line therapy==
==Third-line therapy==
==Subsequent-line therapy==
Category:Ontology pages
Copanlisib (Aliqopa)

==General information==
Class/mechanism: From NCI Drug Dictionary: A phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations.Copanlisib (Aliqopa) package insert Copanlisib (Aliqopa) package insert (locally hosted backup)Aliqopa manufacturer's website
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, or the prescribing information.
==Diseases for which it was used==
*Indolent lymphoma
*Marginal zone lymphoma
==History of changes in FDA indication - WITHDRAWN==
*2017-09-14: Granted accelerated approval for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies. (Based on CHRONOS-1)
**2024-03-18: Accelerated approval for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies withdrawn. (Based on CHRONOS-4)
==Patient Information==
*Copanlisib (Aliqopa) package insert
==Also known as==
*Code name: BAY-80-6946
*Brand name: Aliqopa
==References==
Category:Drugs
Category:Intravenous medications
Category:PI3K alpha inhibitors
Category:PI3K delta inhibitors
Category:Indolent lymphoma medications (historic)
Category:Marginal zone lymphoma medications (historic)
Category:FDA approved in 2017
Category:FDA withdrawn in 2024
Cosibelimab (Unloxcyt)

==Mechanism of action==
From the NCI Drug Dictionary: An immunoglobulin G1 (IgG1), human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, cosibelimab-ipdl specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death protein 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells.
==History of changes in FDA indication==
*2024-12-13: Initial approval for adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. (Based on Study CK-301-101)
==Also known as==
*Code names: CK-301, TG-1501
*Generic name: cosibelimab-ipdl
*Brand name: Unloxcyt
Category:Drugs
Category:Intravenous medications
Category:Anti-PD-L1 antibodies
Category:Cutaneous squamous cell carcinoma medications
Category:FDA approved in 2024
Craniopharyngioma

Back to Top
Last updated on 2024-07-23:1 regimens on this page
1 variants on this page
=Guidelines=
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
==NCCN==
*NCCN does not currently have guidelines at this granular level; please go to the Central Nervous System Cancers category page.
=All lines of therapy=
==Cobimetinib & Vemurafenib==
===Regimen===
Study 	Dates of enrollment 	Evidence
Brastianos et al. 2023 (Alliance A071601)	2018-02-20 to 2020-03-31	Phase 2
====Eligibility criteria====
*Histology: Papillary
====Biomarker eligibility criteria====
*BRAF mutation
====Targeted therapy====
*Cobimetinib (Cotellic) 60 mg PO once per day on days 1 to 21
*Vemurafenib (Zelboraf) 960 mg PO twice per day on days 1 to 28
28-day cycles
===References===
# Alliance A071601: Brastianos PK, Twohy E, Geyer S, Gerstner ER, Kaufmann TJ, Tabrizi S, Kabat B, Thierauf J, Ruff MW, Bota DA, Reardon DA, Cohen AL, De La Fuente MI, Lesser GJ, Campian J, Agarwalla PK, Kumthekar P, Mann B, Vora S, Knopp M, Iafrate AJ, Curry WT Jr, Cahill DP, Shih HA, Brown PD, Santagata S, Barker FG 2nd, Galanis E. BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas. N Engl J Med. 2023 Jul 13;389(2):118-126. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT03224767
Category:Craniopharyngioma regimens
Category:Disease-specific pages
Category:CNS cancers
Crenolanib (CP-868,596)

==Mechanism of action==
From the NCI Drug Dictionary: An orally bioavailable small molecule, targeting the platelet-derived growth factor receptor (PDGFR), with potential antineoplastic activity. Crenolanib binds to and inhibits PDGFR, which may result in the inhibition of PDGFR-related signal transduction pathways, and, so, the inhibition of tumor angiogenesis and tumor cell proliferation.
==Preliminary Data==
# Lewis NL, Lewis LD, Eder JP, Reddy NJ, Guo F, Pierce KJ, Olszanski AJ, Cohen RB. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. J Clin Oncol. 2009 Nov 1;27(31):5262-9. Epub 2009 Sep 8. link to original article link to PMC article EuroPMC
==Also known as==
*Code name: CP-868-596
Category:Drugs
Category:Oral medications
Category:Investigational drugs
Category:FLT3 inhibitors
Category:PDGFR inhibitors
Crizanlizumab (Adakveo)

==Mechanism of action==
Definition from the NCI Drug Dictionary: A humanized monoclonal immunoglobulin G1 anti-P-selectin antibody with vaso-protective and anti-vaso-occlusive properties. Upon administration, crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand-1 (PSGL-1; SELPLG) on neutrophils and monocytes. P-selectin, a glycoprotein that functions as a cell adhesion molecule (CAM), translocates to the surface of activated endothelial cells and platelets, upon stimulation, where it binds to its ligand and mediates the rolling of platelets and neutrophils on activated endothelial cells.
==Diseases for which it is used==
*Sickle cell anemia
==History of changes in FDA indication==
*2019-11-15: Approved to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. (Based on SUSTAIN)
==History of changes in EMA indication==
*2020-10-28: Initial conditional authorization for preventing painful crises in patients with sickle cell disease aged 16 years and older. (Based on SUSTAIN)
==Also known as==
*Code name: SEG-101
*Generic name: crizanlizumab-tmca
*Brand name: Adakveo
Category:Drugs
Category:Intravenous medications
Category:Anti-P-selectin antibodies
Category:Sickle cell anemia medications
Category:EMA approved in 2020
Category:FDA approved in 2019
Custirsen (OGX-011)

==General information==
Class/mechanism: Clusterin inhibitor. Clusterin is upregulated in cancer cells in response to antineoplastic treatment and is hypothesized to play a role in cancer cell survival and treatment resistance. Increased clusterin production has been associated with increased rates of progression, treatment resistance, and shorter survival. Inhibiting clusterin is hypothesized to decrease the rates of tumor growth and resistance to other treatments.OncoGeneX Custirsen pageExperimental Drug Receives Fast Track Designation as Second-Line Chemotherapy for Metastatic Castration-Resistant Prostate Cancer, ASCO Post, 4/23/2014
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Preliminary data==
Note: This is not meant to be an exhaustive list of preliminary results. References included in this section include non-randomized studies published in high-profile journals (e.g., NEJM) and experimental arms of phase 3 RCTs. Inclusion here is not an indication of impending regulatory approval, although many of these drugs do end up receiving approval by a regulatory authority.
===Non-small cell lung cancer===
# Laskin JJ, Nicholas G, Lee C, Gitlitz B, Vincent M, Cormier Y, Stephenson J, Ung Y, Sanborn R, Pressnail B, Nugent F, Nemunaitis J, Gleave ME, Murray N, Hao D. Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. J Thorac Oncol. 2012 Mar;7(3):579-86. EuroPMC
===Prostate cancer===
# Saad F, Hotte S, North S, Eigl B, Chi K, Czaykowski P, Wood L, Pollak M, Berry S, Lattouf JB, Mukherjee SD, Gleave M, Winquist E; Canadian Uro-Oncology Group. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin Cancer Res. 2011 Sep 1;17(17):5765-73. Epub 2011 Jul 25. EuroPMC 
==Patient drug information==
No information available.
==Also known as==
*Code name: CC-8490, OGX-011
==References==
Category:Drugs
Category:Intravenous medications
Category:Clusterin inhibitor
Category:Non-small cell lung cancer medications (investigational)
Category:Prostate cancer medications (investigational) 
Category:Investigational drugs
Cutaneous T-cell lymphoma - null regimens

Back to Top
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main CTCL page for regimens that include active anticancer treatment.
=Early-stage disease=
==Placebo==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Kim et al. 2022 (FLASH)	2015-12 to 2020-11 	Phase 3 (C)	Hypericin 	Seems to have lower cycle 1 ILRR (primary endpoint)Cycle 1 ILRR: 4% vs 16%
No active anticancer treatment.
===References===
#FLASH: Kim EJ, Mangold AR, DeSimone JA, Wong HK, Seminario-Vidal L, Guitart J, Appel J, Geskin L, Lain E, Korman NJ, Zeitouni N, Nikbakht N, Dawes K, Akilov O, Carter J, Shinohara M, Kuzel TM, Piette W, Bhatia N, Musiek A, Pariser D, Kim YH, Elston D, Boh E, Duvic M, Huen A, Pacheco T, Zwerner JP, Lee ST, Girardi M, Querfeld C, Bohjanen K, Olsen E, Wood GS, Rumage A, Donini O, Haulenbeek A, Schaber CJ, Straube R, Pullion C, Rook AH, Poligone B. Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2022 Sep 1;158(9):1031-1039. link to original article link to PMC article EuroPMC NCT02448381
=Relapsed or refractory=
==Placebo==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Prince et al. 2010 (L4389-11)	Not reported 	Phase 3 (C)	1. Denileukin diftitox; 9 mcg/kg2. Denileukin diftitox; 18 mcg/kg	Shorter PFS
No active anticancer treatment.
===References===
# L4389-11: Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, Straus D, Acosta M, Negro-Vilar A. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2010 Apr 10;28(11):1870-7. Epub 2010 Mar 8. link to original article EuroPMC NCT00050999
Category:Cutaneous T-cell lymphoma regimens
Category:Disease-specific pages
Category:Cutaneous lymphomas
Category:T-cell lymphomas
Category:Null regimens
Cutaneous squamous cell carcinoma - null regimens

Back to Top
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main cutaneous SCC page for regimens that include active anticancer treatment.
=Adjuvant therapy=
==Observation==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Brewster et al. 2007	1996-2002 	Phase 3 (C)	Retinoic acid & IFN	Did not meet primary endpoint of TTR or SPT
No further treatment.
====Preceding treatment====
*Surgical resection
===References===
# Brewster AM, Lee JJ, Clayman GL, Clifford JL, Reyes MJ, Zhou X, Sabichi AL, Strom SS, Collins R, Meyers CA, Lippman SM. Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol. 2007 May 20;25(15):1974-8. link to original article EuroPMC
==Placebo==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Awaiting publication (R2810-ONC-1788)	2019-2025 	Phase 3 (C)	Cemiplimab	TBD if different primary endpoint of DFS
No active antineoplastic treatment.
====Preceding treatment====
*Surgical resection and RT
===References===
# R2810-ONC-1788: NCT03969004
Category:Cutaneous squamous cell carcinoma regimens
Category:Disease-specific pages
Category:Non-melanoma skin cancers
Category:Null regimens